| Project/Area Number |
20591521
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
USUI Masanobu Mie University, 大学院・医学系研究科, 講師 (10378341)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Kazushi 三重大学, 医学部附属病院, 助教 (60378370)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 生体肝移植 / CYP3A5 / 遺伝子多型 / テーラーメード治療 / カルシニューリンインヒビター |
|---|
| Research Abstract |
Pharmacokinetics of tacrolims in transplantation, especially a body-weight-based dose, often result in marked individual diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450(CYP)3A5 having polymorphism. In this study, we genotyped CYP3A5 polymorphism and investigated the association between donor/recipient polymorphisms and pharmacokinetics of tacrolimus in living-donor liver transplantation (LDLT). Furthermore we are trying to introduce a tailor-made therapy based on the donor/recipient CYP3A5 polymorphisms. CYP3A5 polymorphism in the recipient as well as the donor highly influences pharmacokinetics of tacrolimus in the LDLT for the long term. Tailor-made treatment based on CYP3A5 genotype is effective to the reduction of the tacrolimus administration, which may reduce the incidence of drug side effect and ACR.
|
